

AERIE PHARMACEUTICALS INC

Form 8-K

June 09, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 8, 2016**

**Aerie Pharmaceuticals, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
  
**of incorporation)**

**001-36152**  
**(Commission File Number)**

**20-3109565**  
**(I.R.S. Employer**

**Identification Number)**

**2030 Main Street, Suite 1500**

**Irvine, California 92614**

**(Address of principal executive offices) (Zip code)**

**Registrant's telephone number, including area code: (949) 526-8700**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( *see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

At the 2016 Annual Meeting of Stockholders of Aerie Pharmaceuticals, Inc. (the Company), held on June 8, 2016, the Company's stockholders (1) elected the persons listed below as directors to serve on the Board of Directors for a three-year term and (2) ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2016.

The table below sets forth the number of votes cast for, against or withheld, and the number of abstentions and broker non-votes, as applicable, for each matter voted upon by the Company's stockholders.

	Votes For	Votes Withheld	Broker Non-Votes	
<b>Proposal 1: Election of Directors</b>				
Gerald D. Cagle, Ph.D.	18,072,077	140,477	5,644,017	
Richard Croarkin	18,109,418	103,136	5,644,017	
	Votes For	Votes Against	Abstentions	Broker Non-Votes
<b>Proposal 2: Ratification of Appointment of</b>				
<b>PricewaterhouseCoopers LLP as</b>				
<b>Independent</b>				
<b>Registered Public Accounting Firm</b>	23,832,164	10,778	13,629	

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**AERIE PHARMACEUTICALS, INC.**

Date: June 9, 2016

By: /s/ Richard J. Rubino  
Richard J. Rubino  
Chief Financial Officer and Secretary